Express Pharma
SEPTEMBER 24, 2023
The psychedelic drug market is on the brink of extraordinary growth, projected to soar to $7.2 billion by 2029, reflecting a robust 55 per cent compound annual growth rate (CAGR). This ascent is propelled by favorable regulatory developments, including pioneering clinical trial guidelines from the FDA. billion in sales in 2029.
European Pharmaceutical Review
FEBRUARY 20, 2024
million by 2029. percent between 2022 and 2029. Other key influences helping the upstream bioprocessing market expand include drug development, antibody manufacturing, as well as a higher need for cell therapy research. Additionally, the research calculated that market is anticipated to undergo a CAGR of 6.85
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
DECEMBER 28, 2023
One of the recent examples is Bayer’s announcement of a cooperation with Shanghai Pharmaceuticals China in November 2023 to set up its first Chinese lab for CGT and cancer drug development. According to GlobalData estimates, the global CGT market is projected to reach $80 billion by 2029.
Pharmaceutical Technology
JUNE 12, 2023
In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. However, 2017 saw the discontinuation of nabiximols from Phase III development in the US for cancer pain, due to lack of efficacy.
European Pharmaceutical Review
OCTOBER 26, 2023
Antibody-drug conjugates (ADCs), such as datopotamab deruxtecan (Dato-DXd) and trastuzumab deruxtecan, have demonstrated compelling evidence of efficacy in oncology across numerous diseases in recent months.
Express Pharma
NOVEMBER 13, 2023
However, tarlatamab, a bispecific T-cell engager (BiTE) developed by Amgen, recently demonstrated potentially registrational data at the European Society for Medical Oncology (ESMO) 2023 Congress from the Phase II DeLLphi-301 trial. The Phase II DeLLphi-301 trial focused on patients with SCLC undergoing two prior treatment regimens.
Putting Patients First Blog
SEPTEMBER 30, 2024
The goal of the rare pediatric disease PRV program is to incentivize drug development for rare pediatric diseases. 3433 the Give Kids a Chance Act, which reauthorized the voucher program through 2029. Earlier this month, the House Energy and Commerce Committee unanimously passed H.R.
Expert insights. Personalized for you.
52 
Let's personalize your content